{
    "clinical_study": {
        "@rank": "80717", 
        "acronym": "BMT-03", 
        "arm_group": {
            "arm_group_label": "Total Marrow Irradiation", 
            "arm_group_type": "Experimental", 
            "description": "Escalating doses of total marrow irradiation (3Gy, 6Gy, or 9Gy) with standard high dose melphalan prior to autologous stem cell rescue."
        }, 
        "brief_summary": {
            "textblock": "In this phase I trial, patients with relapsed or refractory multiple myeloma will receive\n      standard high dose melphalan with autologous stem cell rescue. In addition the\n      pre-transplant conditioning will include targeted total marrow irradiation (TMI). This\n      conventional 3+3 phase I trial will increase the dose of TMI until the maximum tolerated\n      dose (MTD) is reached. Initial patients enrolled will receive the lowest possible dose of\n      3Gy. Maximum dose will be 9Gy."
        }, 
        "brief_title": "Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multiple Myeloma, Relapsed", 
            "Multiple Myeloma, Refractory to Standard Treatment"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who meet the following criteria will be eligible\n\n               -  Patients meeting criteria for symptomatic myeloma\n\n               -  Patients who have progressive myeloma following initial induction (patients may\n                  have received any number of treatment regimens including prior autologous\n                  transplant)\n\n               -  Patient age 18-75 years at time of enrollment\n\n               -  Karnofsky performance status of >70\n\n               -  Cardiac function: LVEF >40%\n\n               -  Hepatic: Bilirubin <2x upper limit of normal and ALT and AST < 2.5x the upper\n                  limit of normal\n\n               -  Renal: Creatinine clearance of >30mL/min, estimated or calculated\n\n               -  Pulmonary: DLCO, FEV1, FVC >50% of predicted (after correction for hemoglobin)\n\n        Exclusion Criteria:\n\n          -  Patients with the following will be ineligible for registration\n\n               -  Patients with diagnosis of plasma cell leukemia\n\n               -  Patients with truly non secretory myeloma (patients with light chain disease are\n                  eligible)\n\n               -  Pregnant or breast-feeding\n\n               -  Uncontrolled viral, fungal or bacterial infection Note: Infection is permitted\n                  if there is evidence of response to medication. Eligibility of HIV infected\n                  patients will be determined on a case-by-case basis.\n\n               -  Patients who have undergone prior allogeneic stem cell transplant\n\n               -  Prior solid organ transplant\n\n               -  Patients receiving prior radiation to more than 20% of bone marrow containing\n                  areas"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043847", 
            "org_study_id": "2013-0201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Total Marrow Irradiation", 
                "description": "Subjects in this trial will receive total marrow irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, or 9Gy.", 
                "intervention_name": "Total Marrow Irradiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Total Marrow Irradiation", 
                "description": "Subjects will receive standard melphalan 200mg/m2 (100mg/m2 day-2 and day-1) conditioning therapy prior to transplant.", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug", 
                "other_name": "Alkeran \u00ae"
            }, 
            {
                "arm_group_label": "Total Marrow Irradiation", 
                "description": "Subjects to begin GCSF 5 \u03bcg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm3 over period of 3 days.", 
                "intervention_name": "Filgrastim (G-CSF)", 
                "intervention_type": "Drug", 
                "other_name": "Neupogen\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Melphalan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Myeloma", 
            "Relapsed", 
            "Refractory", 
            "Progressive Disease", 
            "Symptomatic"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "contact": {
                "email": "prpatel8@uic.edu", 
                "last_name": "Pritesh Patel, MD", 
                "phone": "312-996-5762"
            }, 
            "contact_backup": {
                "email": "alishaw@uic.edu", 
                "last_name": "Alisha Williams, RN", 
                "phone": "312-413-2746"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60612"
                }, 
                "name": "University of Illinois Cancer Center"
            }, 
            "investigator": {
                "last_name": "Pritesh Patel, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To establish the maximal tolerated dose of total marrow irradiation which can be added to high dose melphalan conditioning in patients with multiple myeloma undergoing autologous stem cell transplant for relapsed/ refractory myeloma.", 
            "measure": "Maximum tolerated dose of TMI", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 60 days post-transplant."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043847"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Illinois at Chicago", 
            "investigator_full_name": "Pritesh Patel, MD", 
            "investigator_title": "Faculty, Asst. Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To evaluate progression free survival (PFS) and in patients with multiple myeloma (relapsed or refractory) undergoing autologous stem cell transplant using the combination of high dose melphalan and total marrow irradiation.", 
            "measure": "Progression Free Survival", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 1 year post-transplant."
        }, 
        "source": "University of Illinois at Chicago", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Illinois at Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}